ADVB ADVB
Company Profile ↓Company Overview
ADVB (ADVB) is a publicly traded company listed on with a market capitalization of $8.59M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.08.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -8.53% |
| 6 Months: | +43.32% |
| 3 Months: | +15.74% |
| 1 Month: | +48.41% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)48.75 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 58.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 280.06K | 567.51K | 523.91K | 396.64K | 519.84K |
| Operating Income | - | - | - | -280.06K | -567.51K | -523.91K | -396.64K | -519.84K |
| EBITDA | - | - | - | -280.06K | -545.00K | -475.92K | -396.64K | -479.50K |
| Interest Expense | - | - | - | - | - | - | - | 112 |
| Pretax Income | - | - | - | -579.49K | -1.20M | -386.90K | 7.00M | -488.94K |
| Tax Provision | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | -145.34K | -1.06M | -265.58K | -907.90K | -1.38M | -386.90K | 6.86M | -488.94K |
| Diluted EPS | -0.01 | -0.05 | -0.01 | -0.84 | -1.35 | -0.40 | 6.20 | -0.38 |
| R&D Expense | 188.39K | 313.51K | 181.70K | 212.40K | 219.97K | 235.99K | 186.33K | 243.23K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | - |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 2.37M | 3.07M | 2.54M | - |
| Operating Income | -2.37M | -3.07M | -2.54M | - |
| EBITDA | -2.24M | -2.71M | -2.14M | - |
| Interest Expense | - | - | - | - |
| Pretax Income | -4.03M | -3.73M | -2.78M | - |
| Tax Provision | 0 | 0 | 0 | - |
| Net Income | -4.03M | -3.73M | -2.78M | - |
| Diluted EPS | -0.64 | -3.45 | -2.57 | -3.20 |
| R&D Expense | - | - | 880.19K | 909.77K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Total Assets | 6.71M | 4.60M | 4.46M | - |
| Current Assets | 5.01M | 2.79M | 3.05M | - |
| Cash & Equivalents | 4.78M | 2.62M | 2.61M | - |
| Inventory | - | - | - | - |
| Receivables | 162.52K | 149.95K | 205.18K | - |
| Total Liabilities | 3.22M | 3.29M | 2.80M | - |
| Current Liabilities | 2.99M | 3.28M | 2.73M | - |
| Long Term Debt | - | - | - | - |
| Total Debt | 468.87K | 235.37K | 126.74K | - |
| Total Equity | 3.49M | 1.31M | 1.66M | - |
| Shares Outstanding | 1.08M | 1.08M | 1.08M | 1.08M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -741.45K | -2.96M | -2.13M | -5.83M |
| Investing Cash Flow | -1.08M | -263.01K | -74.11K | -31.65K |
| Financing Cash Flow | 6.10M | 458.14K | 1.87M | 5.93M |
| Capital Expenditure | -1.31M | -212.52K | -74.11K | -31.65K |
| Free Cash Flow | -2.05M | -3.18M | -2.20M | -5.86M |
| Net Change in Cash | 4.27M | -2.77M | -333.63K | - |
Ratios (Annual)
Figures in %.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | -115.4% | -285.9% | -167.3% | - |
| ROCE % | -63.8% | -231.9% | -147.1% | - |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ADVB
Advanced Biomed Inc. Announces 1 for 20 Share Consolidation
Tainan City, Taiwan, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company” or “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision …
Advanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
Tainan, Taiwan, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicin…
Advanced Biomed sells Hong Kong subsidiary for $23,000
Advanced Biomed (ADVB) entered into an agreement with an unrelated third party, Wei Ha Hui, pursuant to which the Company agreed to sell 100% of the issued and outstanding shares of Advanced Biomed Limited, a Hong Kong company and a wholly …
Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary
Tainan City, Taiwan, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision me…
Advanced Biomed Inc. Announces Launch of A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
[Tainan City], Taiwan, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision…
ADVB — Frequently Asked Questions
What is the current share price of ADVB?
As of 2026-08-05 17:25 PDT, ADVB trades at $7.94 on NASDAQ/NYSE. Its 52-week range is $3.71 to $18.98.
What is the market capitalisation of ADVB?
ADVB has a market capitalisation of $8.59M on NASDAQ/NYSE.
What is the P/E ratio of ADVB?
ADVB trades at a trailing price-to-earnings (P/E) ratio of -2.48. Its price-to-book (P/B) ratio is 5.17.
Is ADVB a good stock to buy?
This page provides a data-driven analysis of ADVB, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.